What pharmaceutical concept stocks are there?

According to the statistics of straight flush (59.61-1.10%, buy), the market research center of Securities Daily shows that up to now, 67 listed companies in the pharmaceutical industry have disclosed the interim results forecast of 20 17, and the number of companies with pre-recorded results has reached 50. Buy), Rheinland Bio (10.47 +0.29%, buy), Kangrui Pharmaceutical (16.56 +0.79%, buy), Yongan Pharmaceutical (26. 15 +5. 15%) Buy), Guangyuyuan (37.93 +2.5 1%, buy) and other six companies expect that the net profit will double in the first half of 20 17, and Asia Pacific Pharmaceutical (28.94 -0.2 1%, buy) and Gloria Ying (1). Buy), Unnamed Pharmaceutical (22.05 +0. 14%, buy), Dongcheng Pharmaceutical (14.3, suspend trading, buy), Jindawei (12.25 +0.4 1%, buy).

Guolian Securities believes that the rapid growth of pharmaceutical listed companies is closely related to the rapid integration of mergers and acquisitions and the concentration of market share to leading enterprises during the industry reform. Most listed companies have a high status in the industry and have strong advantages in management, capital and technology. Under the background of industry reform, leading enterprises are expected to continue to benefit.

In terms of valuation, the latest dynamic P/E ratio of 45 stocks in the above interim report is lower than the average level of the pharmaceutical industry (66.33 times), and the dynamic P/E ratio of Xincheng Hehecheng is the lowest, which is 15. 12 times, Yifan Pharmaceutical (14.98 +0.8 1%, buy) and The latest dynamic P/E ratios of Buy and Zhongsheng Pharmaceutical (1 1.50 +0.35%, Buy) are 2 1.3 1 times, 2 1.56 times and 2 1.60 times respectively.